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Edited by Gunnar von Heijne and Anders LiljasAbstract It has long been the goal of molecular biologists to de-
sign DNA-binding proteins for the speciﬁc control of gene
expression. The zinc ﬁnger design is ideally suited for such pur-
poses, discriminating between closely related sequences both in
vitro and in vivo. Whereas other DNA-binding proteins generally
make use of the 2-fold symmetry of the double helix, zinc ﬁngers
do not and so can be linked linearly in tandem to recognize DNA
sequences of diﬀerent lengths, with high ﬁdelity. This modular
design oﬀers a large number of combinatorial possibilities for
the speciﬁc recognition of DNA. By fusing zinc ﬁnger peptides
to repression or activation domains, genes can be selectively tar-
geted and switched oﬀ and on. Several recent applications of such
engineered zinc ﬁnger proteins (ZFPs) are described, including
the activation of vascular endothelial growth factor (VEGF) in
a human cell line and an animal model. Clinical trials have re-
cently begun on using VEGF-activating ZFPs to treat human
peripheral arterial disease, by stimulating vascular growth. Also
in progress are pre-clinical studies using ZFPs to target the
defective genes in two monogenic disorders, SCID and SCA.
The aim is to replace them in each case by a correct copy from
an extrachromosomal DNA donor by means of homologous
recombination. Promising results are reported.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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ZFPs of the classical Cys2His2 type are the most frequently
used class of transcription factor and account for about 3% of
genes in the human genome. The zinc-ﬁnger motif was discov-
ered during our biochemical studies on the transcription factor
TFIIIA, which regulates the expression of the 5S ribosomal
RNA genes of Xenopus laevis [1].
The C2H2 motif consists of a sequence of about 30 amino
acids containing two histidines, two cysteines and three hydro-
phobic residues, which are all at conserved positions. It forms
a small, independently folded domain stabilized by Zn2+,
which can be used repeatedly in a modular tandem fashion
to achieve sequence-speciﬁc recognition of DNA. The domains
all have the same structural framework, but achieve chemical
distinctiveness through variations in key residues. This modu-*Fax: +44 1223 412231.
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ities for DNA recognition [1,2] so it is no wonder that zinc-
ﬁnger domains are so widely found in nature.
Structurally, the domain is composed of a b-hairpin and a a-
helix pinned together by Zn2+. In the canonical Zif268 docking
arrangement, the primary contacts are made by the a-helix,
which binds in the DNA major groove through primary
hydrogen-bond interactions from helical positions – 1, 3 and
6 to three successive bases on one strand of the DNA, and also
through a secondary interaction from helical position 2 to the
other strand [3].
We have used the technique of phage display to create a
large library (or repertoire) of diﬀerent zinc ﬁngers from which
selections are made for speciﬁc binding to a given DNA se-
quence triplet, and which can discriminate between closely re-
lated triplets, e.g., GCG and GTG. From this database, there
have been elucidated elements of recognition rules that relate
the amino acid sequence of a ﬁnger motif to its preferred
DNA-binding site [4].
Control of gene expression, using such speciﬁcally selected
combinations of three zinc-ﬁnger motifs, was originally dem-
onstrated by the speciﬁc inhibition of an oncogene in a mouse
cancer cell line and also, conversely, by activating a model gene
in an expression plasmid [5]. These experiments showed that
zinc-ﬁnger DNA-binding domains can be engineered de novo
to target given promoter DNA sequences, and, by fusing them
to an eﬀector domain, to regulate their activity.
A peptide made of three zinc ﬁngers recognizes nine base
pairs, a sequence which would occur randomly many thousand
times in a large genome. Six ﬁngers linked together would rec-
ognise a DNA sequence 18 base pairs in length, suﬃciently
long to constitute a rare address in the human genome. How-
ever, the natural periodicity of the zinc ﬁnger repeat does not
quite match the periodicity of the bases in the DNA double he-
lix, so extensions of the peptide beyond three ﬁngers tend to
get out of register. Over the last few years, we have learned
how to engineer longer runs of zinc ﬁngers which can target
longer DNA sequences [6]. The use of six-ﬁnger peptides has
been demonstrated to give virtually single gene speciﬁcity [7].
These peptides are assembled out of libraries of 2-ﬁnger or
3-ﬁnger peptides developed in Cambridge for speciﬁc DNA se-
quences, after our earlier selections of speciﬁc single ﬁngers.
We thus possess a catalogue of zinc ﬁngers, which can virtually
uniquely target any gene sequence of interest. These have been
supplied by the MRC to the Californian Biotech Company
Sangamo Biosciences.
By adding functional groups to the engineered DNA-
binding domains (DBDs), e.g., silencing or activation do-blished by Elsevier B.V. All rights reserved.
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downregulate expression of a target gene. Other eﬀector do-
mains can also be fused to the DBDs, e.g., recombinases or
nucleases. Some applications by ourselves in Cambridge and
others, including Sangamo Biosciences, will be described:
(i) The disruption of the infective cycle of infection by her-
pes simplex virus [8].
(ii) Inhibition of HIV-1 expression [9].
(iii) Activating the expression of erythropoietin (EPO) in a
human kidney cell line [10].
(iv) Activating the expression of vascular endothelial growth
factor (VEGF) in a human cell line, and in an animal
model [11,12].
While not germane to the present discussion, a new result
may be worth including. While, it has long been known that
TFIIIA itself binds RNA as well as DNA, there is now
increasing evidence that zinc ﬁngers are more widely used
to recognize RNA. However, the molecular basis of the rec-
ognition has remained elusive. We have recently determined
the X-ray structure of a zinc-ﬁnger RNA complex, which re-
veals two modes of zinc-ﬁnger binding, both diﬀerent from
that for DNA [13].2. Stimulation of new vasculature by engineered ZFPs
Following the work at Sangamo on the activation of the
transcription factor VEGF by ZFPs in mouse and human cells
lines [11], experiments showed that new blood vessels could be
formed in a mouse ear, which did not leak, unlike the results
which have been obtained by other workers who have been
delivering various cDNA spliced isoforms of the gene [12].
The reason for the success with ZFP activation is that the lat-
ter acts on the promoter of the VEGF gene, and hence all
spliced isoforms are produced when the gene is induced to pro-
mote angiogenesis.
Subsequent work by Frank Giordano at Yale and Brian An-
nex at Duke University showed increased blood ﬂow in hind-
limbs of ischaemic rabbits, with the ZFP delivered by a
retrovirus or simply by injecting the DNA. On the basis of this
and other conﬁrmatory work, Sangamo was granted in March
2004 an IND by the FDA to begin clinical trials to evaluate the
ability of an appropriate ZFP to stimulate the natural growth
of normal blood vessels in treating claudication, a symptom of
peripheral arterial disease that is caused by poor blood ﬂow to
the legs. The trials are being funded by Edwards Life Sciences
Corporation, who believe that the ZFP could ultimately have
possible use in ischemic cardiac disease, if an eﬀective delivery
system can be devised.3. Gene correction by homologous recombination using zinc-
ﬁnger nucleases
Gene correction is the process by which sequence altera-
tions in defective or deleterious genes can be changed or
‘‘corrected’’ by homologous recombination (HR)-mediated
gene conversion between the target locus and a donor con-
struct encoding the corrective sequence. Monogenic disorders
such as X-linked severe combined immune deﬁciency
(SCID), sickle-cell anemia (SCA), haemophilia and Gau-chers disease are caused by the inheritance of defective al-
leles of a single gene. The ability to replace this gene
sequence via HR-mediated gene correction has the potential
of fully restoring the gene function and providing a perma-
nent cure for patients with these disorders. However, this
process is highly ineﬃcient in that the frequency of unaided
HR at a speciﬁc locus occurs in only about 1 in 105 cells.
This is far below a level that would be considered therapeu-
tic. A double-stranded break (DSB) has been demonstrated
to potentiate HR at a speciﬁc genetic locus by 5000-fold
[14]. Therefore, the introduction of a corrective donor se-
quence together with a site-speciﬁc nuclease that would pro-
duce a DSB at or near the location of the mutation could
stimulate Gene Correction to levels that would provide a
therapeutic impact.
The focus of the project at Sangamo Biosciences by Michael
Holmes and Fyodor Urnov is to use engineered ZFPs, fused to
the non-speciﬁc cleavage domain of the Fok1 restriction en-
zyme, to create DSBs at speciﬁc sites of mutation in the human
genome, and thereby, stimulate homologous recombination at
sites responsible for monogenic disorders. This type of ZFP-
nuclease, introduced as pairs with tandem binding sites engi-
neered in opposite orientation, with 6-bp spacing separating
the two half sites, has previously been shown to produce cor-
rections of the order of 10–30% in model systems or cell lines
[15,16]. Such results mean that gene therapy can become a
practical possibility.
The work at Sangamo on model systems has shown that, the
closer the DSB is to the DNA sequence to be replaced (prefer-
ably within the sequence), the more eﬀective the gene correc-
tion. Zinc-ﬁnger sequences can be designed and/or selected
to meet this requirement with high speciﬁcity. Currently four
ﬁnger peptides are in use and six ﬁnger peptides could be used
to give eﬀectively single gene speciﬁcity.
The results so far in collaboration with Matthew Porteus,
give corrections of 10–15% for SCID in somatic K562 cells
and 3% in the b globin gene for SCA. The next step for
SCID is to isolate CD34 progenitor cells from the patients
bone marrow and transfect them with a pair of ZFP nuc-
leases and a corrective donor construct. These cells would un-
dergo gene correction, be allowed to expand and re-
introduced into the bone marrow to repopulate the bone
marrow with corrected cells. Sangamo hope to apply for an
IND for SCID disease next year and gene correction may be-
come a reality.
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